$ATXI
AVENUE THERAPEUTICS, INC.

2019 Q2 Form 10-Q Financial Statement

#000114420419025546 Filed on May 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $720.0K $1.120M $1.390M
YoY Change -22.58% 13.13% 26.36%
% of Gross Profit
Research & Development $6.390M $10.24M $2.720M
YoY Change 70.22% 8.5% -47.89%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.110M $10.24M $4.100M
YoY Change 89.4% 8.5% -35.18%
Operating Profit -$11.36M
YoY Change 8.97%
Interest Expense $130.0K $90.00K $10.00K
YoY Change -87.5%
% of Operating Profit
Other Income/Expense, Net $180.0K
YoY Change 119.51%
Pretax Income -$6.980M -$11.27M -$3.920M
YoY Change 49.79% 8.57% -37.18%
Income Tax
% Of Pretax Income
Net Earnings -$6.980M -$11.27M -$3.920M
YoY Change 49.88% 8.6% -37.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$428.0K -$820.2K -$380.2K
COMMON SHARES
Basic Shares Outstanding 16.56M 16.50M 10.66M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.46M $29.45M $2.670M
YoY Change 72.93% 96.86% -87.74%
Cash & Equivalents $10.46M $29.45M $2.671M
Short-Term Investments $5.000M $0.00
Other Short-Term Assets $220.0K $310.0K $1.850M
YoY Change -56.0% 0.0% 374.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $15.68M $29.76M $4.530M
YoY Change 66.1% 94.89% -79.57%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $3.000K -$5.000K
YoY Change -100.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $15.68M $29.76M $4.530M
Total Long-Term Assets $0.00 $3.000K -$5.000K
Total Assets $15.68M $29.76M $4.525M
YoY Change 66.17% 94.87% -79.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $850.0K $7.259M $3.089M
YoY Change -73.39% 85.7% 99.94%
Accrued Expenses $920.0K $2.150M $2.070M
YoY Change -25.2% 6.97% 4040.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.770M $9.412M $5.156M
YoY Change -59.95% 58.99% 84.8%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.770M $9.412M $5.156M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.770M $9.412M $5.156M
YoY Change -59.95% 58.99% 84.8%
SHAREHOLDERS EQUITY
Retained Earnings -$53.48M -$42.21M
YoY Change 72.3% 104.29%
Common Stock $73.83M $41.58M
YoY Change 82.79% 6.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.90M $20.35M -$631.0K
YoY Change
Total Liabilities & Shareholders Equity $15.68M $29.76M $4.525M
YoY Change 66.17% 94.87% -79.59%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$6.980M -$11.27M -$3.920M
YoY Change 49.88% 8.6% -37.21%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$13.98M -$5.568M -$1.240M
YoY Change 132.23% -18.35% -70.96%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$5.000M $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$5.000M $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $35.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -20.00K 32.35M -900.0K
YoY Change
NET CHANGE
Cash From Operating Activities -13.98M -5.568M -1.240M
Cash From Investing Activities -5.000M 0.000 0.000
Cash From Financing Activities -20.00K 32.35M -900.0K
Net Change In Cash -19.00M 26.78M -2.140M
YoY Change 215.61% 741.78% -49.88%
FREE CASH FLOW
Cash From Operating Activities -$13.98M -$5.568M -$1.240M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10241000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29448000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2671000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
254000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
152000
CY2019Q1 us-gaap Assets
Assets
29763000
CY2018Q4 us-gaap Assets
Assets
4525000
CY2019Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9326000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4669000
CY2019Q1 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
86000
CY2018Q4 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
487000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9412000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5156000
CY2019Q1 us-gaap Liabilities
Liabilities
9412000
CY2018Q4 us-gaap Liabilities
Liabilities
5156000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
2000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
73827000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41577000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53478000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42209000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
20351000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-631000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29763000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4525000
CY2019Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1315317
CY2018Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
984999
CY2019Q1 atxi Service Agreement Expenses
ServiceAgreementExpenses
0
CY2018Q1 atxi Service Agreement Expenses
ServiceAgreementExpenses
100000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3089000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
7259000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
463000
CY2019Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
130000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1117000
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1937000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4669000
CY2019Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9326000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.29
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-10377000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.03
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2019Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2655000
CY2018Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32345000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2019Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
26777000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
102000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-78000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5453000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3016000
CY2019Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-401000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1119000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
986000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11360000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10425000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
91000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
48000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11269000
CY2018Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
114000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5568000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6819000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10000000
CY2019Q1 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
0
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9439000
CY2018Q1 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-10000000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35000000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13742649
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10099331
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-631000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
751000
CY2019Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
31500000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
19380000
CY2018Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y7M17D
CY2019Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
61000
CY2018Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1702000
CY2019Q1 atxi Share Issued During Period Valueon Exercise Of Warrants
ShareIssuedDuringPeriodValueonExerciseOfWarrants
0
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
20351000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350000
CY2018Q1 atxi Share Issued During Period Valueon Exercise Of Warrants
ShareIssuedDuringPeriodValueonExerciseOfWarrants
0
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
9353000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11269000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-10377000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
751000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
350000
CY2018Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
3181000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2671000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11782000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29448000
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14963000
CY2019Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
12000
CY2018Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16557122
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10667714
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10667714
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16557122
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.05in;margin-top: 0;text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.05in; margin-top: 0px; text-align: justify; text-indent: 0.23in; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; text-align: justify;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
20000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.29
CY2019Q1 us-gaap Business Acquisition Share Price
BusinessAcquisitionSharePrice
6.00
CY2019Q1 us-gaap Business Acquisition Equity Interest Issued Or Issuable Value Assigned
BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
31500000
CY2019Q1 us-gaap Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
5833333
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
AVENUE THERAPEUTICS, INC.
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001644963
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Trading Symbol
TradingSymbol
ATXI
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16559247
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-19-025546-index-headers.html Edgar Link pending
0001144204-19-025546-index.html Edgar Link pending
0001144204-19-025546.txt Edgar Link pending
0001144204-19-025546-xbrl.zip Edgar Link pending
atxi-20190331.xml Edgar Link completed
atxi-20190331.xsd Edgar Link pending
atxi-20190331_cal.xml Edgar Link unprocessable
atxi-20190331_def.xml Edgar Link unprocessable
atxi-20190331_lab.xml Edgar Link unprocessable
atxi-20190331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv520739_10q.htm Edgar Link pending
tv520739_ex31-1.htm Edgar Link pending
tv520739_ex31-2.htm Edgar Link pending
tv520739_ex32-1.htm Edgar Link pending
tv520739_ex32-2.htm Edgar Link pending